Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Midas Pharma
Midas Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ranivisio
Ranibizumab
2022-08-25
Diabetes complications
,
Macular edema
,
Retinal vein occlusion
,
Diabetic retinopathy
,
Wet macular degeneration
,
Choroidal neovascularization
,
Degenerative myopia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Angiotensin ii
peripheral arterial disease
,
peripheral vascular diseases
,
infections
,
fibrosis
,
hiv infections
,
acquired immunodeficiency syndrome
,
communicable diseases
,
type 1 diabetes mellitus
,
polycystic kidney diseases
,
essential hypertension
,
marfan syndrome
,
pathologic dilatation
,
syndrome
,
arachnodactyly
,
hypertension
,
kidney diseases
,
chronic obstructive pulmonary disease
,
emphysema
,
chronic bronchitis
,
bronchitis
,
pulmonary emphysema
,
smoking
,
obesity
,
insulin resistance
,
hyperglycemia
,
proteinuria
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use